| 000 | 27603cam a22005774a 4500 | ||
|---|---|---|---|
| 003 | OSt | ||
| 005 | 20240322151847.0 | ||
| 006 | m d | ||
| 007 | co ugu|||||||| | ||
| 008 | 060501t20072007moua b 001 0 eng | ||
| 020 | _a1416025529 | ||
| 020 | _a9781416025528 | ||
| 040 |
_aDNLM/DLC _beng _cKAMPALA UNIVERSITY NURSING SCHOOL _dKAMPALA UNIVERSITY NURSING SCHOOL _eRDA |
||
| 050 | 0 | 0 |
_aRM 301 _b.P457 2007 |
| 060 | 1 | 0 |
_aQV 4 _bL 523 2007 |
| 100 | 1 |
_aLehne, Richard A., _d1943- _eauthor _93878 |
|
| 245 | 1 | 0 |
_aPharmacology for nursing care / _cRichard A. Lehne, |
| 250 | _a6th ed | ||
| 260 |
_aCanada: _bElsevier; _c2007 |
||
| 300 |
_axxii, 1,354 p. : _bcol, ill ; _c29 cm + _e1 CD-ROM (4 3/4 in.) |
||
| 504 | _aIncludes bibliographical references and index | ||
| 505 | 0 | 0 |
_g[pt]. 1. _tIntroduction -- _g1. _tOrientation to pharmacology -- _tFour basic terms -- _tProperties of an ideal drug -- _tThe therapeutic objective -- _tFactors that determine the intensity of drug responses -- _g2. _tApplication of pharmacology in nursing practice -- _tEvolution of nursing responsibilities regarding drugs -- _tApplication of pharmacology in patient care -- _tApplication of pharmacology in patient education -- _tApplication of the nursing process in drug therapy -- _g3. _tDrug regulation, development, names, and information -- _tLandmark drug legislation -- _tNew drug development -- _tDrug names -- _tOver-the-counter drugs -- _tSources of drug information -- _g[pt]. 2. _tBasic principles of pharmacology -- _g4. _tPharmacokinetics -- _tApplication of pharmacokinetics in therapeutics -- _tA note to chemophobes -- _tPassage of drugs across membranes -- _tAbsorption -- _tDistribution -- _tMetabolism-- _tExcretion -- _tTime course of drug responses -- _g5. _tPharmacodynamics -- _tDose-response relationships -- _tDrug-receptor interactions -- _tDrug responses that do not involve receptors -- _tInterpatient variability in drug responses -- _tThe therapeutic index -- _g6. _tDrug interactions -- _tDrug-drug interactions -- _tDrug-food interactions -- _tDrug-herb interactions |
| 505 | 0 | 0 |
_g7. _tAdverse drug reactions and medication errors -- _tAdverse drug reactions -- _tMedication errors -- _g8. _tIndividual variation in drug responses -- _tBody weight and composition -- _tAge -- _tPathophysiology -- _tTolerance -- _tPlacebo effect -- _tVariability in absorption -- _tGenetics -- _tGender -- _tRace -- _tFailure to take medicine as prescribed -- _tDrug interactions -- _tDiet |
| 505 | 0 | 0 |
_g[pt]. 3. _tDrug therapy across the lifespan -- _g9. _tDrug therapy during pregnancy and breast-feeding -- _tDrug therapy during pregnancy : basic considerations -- _tDrug therapy during pregnancy : teratogenesis -- _tDrug therapy during breast-feeding -- _g10. _tDrug therapy in pediatric patients -- _tPharmacokinetics : neonates and infants -- _tPharmacokinetics : children 1 year and older -- _tAdverse drug reactions -- _tDosage determination -- _tPromoting adherence -- _g11. _tDrug therapy in geriatric patients -- _tPharmacokinetic changes in the elderly -- _tPharmacodynamic changes in the elderly -- _tAdverse drug reactions and drug interactions -- _tPromoting adherence -- _g[pt]. 4. _tPeripheral nervous system drugs -- _tIntroduction -- _g12. _tBasic principles of neuropharmacology -- _tHow neurons regulate physiologic processes -- _tBasic mechanisms by which neuropharmacologic agents act -- _g13. _tPhysiology of the peripheral nervous system -- _tDivisions of the nervous system -- _tOverview of autonomic nervous system functions -- _tBasic mechanisms by which the autonomic nervous system regulates physiologic processes -- _tAnatomic considerations -- _tIntroduction to transmitters of the peripheral nervous system -- _tIntroduction to receptors of the peripheral nervous system -- _tExploring the concept of receptor subtypes -- _tLocations of receptor subtypes -- _tFunctions of cholinergic and adrenergic receptor subtypes -- _treceptor specificity of the adrenergic receptor subtypes -- _tReceptor specificity of the adrenergic transmitters -- _tTransmitter life cycles |
| 505 | 0 | 0 |
_tCholinergic drugs -- _g14. _tMuscarinic agonists and antagonists -- _tMuscarinic agonists -- _tMuscarinic antagonists (anticholinergic drugs) -- _g15. _tCholinesterase inhibitors and their use in myasthenia gravis -- _tReversible cholinesterase inhibitors -- _t"Irreversible" cholinesterase inhibitors -- _tMyasthenia gravis -- _g16. _tDrugs that block nicotinic cholinergic transmission : neuromuscular blocking agents and ganglionic blocking agents -- _tNeuromuscular blocking agents -- _tGanglionic blocking agents -- _tAdrenergic drugs -- _g17. _tAdrenergic agonists -- _tMechanisms of adrenergic receptor activation -- _tOverview of the adrenergic agonists -- _tTherapeutic applications and adverse effects of adrenergic receptor activation -- _tProperties of representative adrenergic agonists -- _tDiscussion of adrenergic agonists in other chapters -- _g18. _tAdrenergic antagonists -- _tAlpha-adrenergic antagonists 1 : therapeutic and adverse responses to alpha blockade -- _tAlpha-adrenergic antagonists 2 : properties of individual alpha blockers -- _g19. _tIndirect-acting antiadrenergic agents -- _tAdrenergic neuron-blocking agents -- _tCentrally acting alpha₂ agonists |
| 505 | 0 | 0 |
_g[pt]. 5. _tCentral nervous system drugs -- _g20. _tIntroduction to central nervous system pharmacology -- _tTransmitters of the CNS -- _tThe blood-brain barrier -- _tHow do CNS drugs produce therapeutic effects? -- _tAdaptation of the CNS to prolonged drug exposure -- _tDevelopment of new psychotherapeutic drugs -- _tApproaching the study of CNS drugs -- _tDrugs for neurodegenerative disorders -- _g21. _tDrugs for Parkinson's disease -- _tPathophysiology of Parkinson's disease -- _tOverview of drug therapy -- _tPharmacology of the drugs used for Parkinson's disease -- _g22. _tAlzheimer's disease -- _tPathophysiology of Alzheimer's disease -- _tRisk factors, symptoms, and diagnosis -- _tDrug therapy -- _g23. _tDrugs for multiple sclerosis -- _tOverview of MS and its treatment -- _tDisease modifying drugs 1 : immunomodulators -- _tDisease modifying drugs 2 : immunosuppressants -- _tDrugs used to manage MS symptoms -- _tNeurologic drugs -- _g24. _tDrugs for epilepsy -- _tSeizure generation-- _tTypes of seizures -- _tHow antiepileptic drugs work -- _tBasic therapeutic considerations -- _tClassification of antiepileptic drugs -- _tTraditional antiepileptic drugs -- _tNewer antiepileptic drugs -- _tManagement of epilepsy during pregnancy -- _tManagement of generalized convulsive status epilepticus |
| 505 | 0 | 0 |
_g25. _tDrugs for muscle spasm and spasticity -- _tSeizure generation -- _tTypes of seizures -- _tHow antiepileptic drugs work -- _tBasic therapeutic considerations-- _tClassification of antiepileptic drugs -- _tTraditional antiepileptic drugs -- _tNewer antiepileptic drugs -- _tManagement of epilepsy during pregnancy -- _tManagement of generalized convulsive status epilepticus -- _tDrugs for pain -- _tDrug therapy of muscle spasm : centrally acting muscle relaxants -- _tDrugs for spasticity -- _g26. _tLocal anesthetics -- _tBasic pharmacology of the local anesthetics -- _tProperties of individual local anesthetics -- _tClinical use of local anesthetics -- _g27. _tGeneral anesthetics -- _tBasic pharmacology of the inhalation anesthetics -- _tProperties of individual inhalation anesthetics -- _tIntravenous anesthetics -- _g28. _tOpioid (narcotic) analgesics, opioid antagonists, and nonopioid centrally acting analgesics --Introduction to the opioids -- _tBasic pharmacology of the opioids -- _tClinical use of opioids -- _tOpioid antagonists -- _tNonopioid centrally acting analgesics -- _g29. _tPain management in patients with cancer -- _tPathophysiology of pain -- _tManagement strategy -- _tAssessment and ongoing evaluation -- _tDrug therapy -- _tNondrug therapy -- _tPain management in special populations -- _tpatient education -- _tJCAHO pain management standards |
| 505 | 0 | 0 |
_g30. _tDrugs for headache -- _tMigraine headache 1 : characteristics and overview of treatment -- _tMigraine headache 2 : abortive therapy -- _tMigraine headache 3 : preventive therapy -- _tCluster headaches -- _tTension[type headache -- _tPsychotherapeutic drugs -- _g31. _tAntipsychotic agents and their use in schizophrenia -- _tSchizophrenia : clinical presentation and etiology-- _tConventional antipsychotic agents 1 : group properties -- _tConventional antipsychotic agents 2 : properties of individual agents -- _tAtypical antipsychotic agents -- _tManagement of schizophrenia -- _g32. _tAntidepressants -- _tMajor depression : clinical features, pathogenesis, and treatment modalities -- _tSuicide risk with antidepressant drugs -- _tTricyclic antidepressants -- _tSelective serotonin reuptake inhibitors (SSRIs) -- _tSerotonin/norepinephrine reuptake inhibitors (S/NRIs) -- _tMonoamine oxidase inhibitors (MAOIs) -- _tAtypical antidepressants -- _tElectroconvulsive therapy -- _tVagus nerve stimulation -- _g33. _tDrugs for bipolar disorder -- _tCharacteristics of bipolar disorder -- _tTreatment of bipolar disorder -- _tMood-stabilizing drugs -- _tAntipsychotic drugs -- _g34. _tSedative-hypnotic drugs -- _tBenzodiazepines -- _tBenzodiazepine-like drugs -- _tRamelteon : a melatonin agonist -- _tBarbiturates -- _tMiscellaneous sedative-hypnotics -- _tManagement of transient insomnia |
| 505 | 0 | 0 |
_g35. _tManagement of anxiety disorders -- _tGeneralization anxiety disorder -- _tPanic disorder -- _tObsessive-compulsive disorder -- _tSocial anxiety disorder (social phobia) -- _tPost-traumatic stress disorder -- _g36. _tCentral nervous system stimulants and attention-deficit/hyperactivity disorder -- _tAmphetamines -- _tMethylphenidate and dexmethylphenidate -- _tMethylxanthines -- _tMiscellaneous CNS stimulants -- _tAttention-deficit/hyperactivity disorder -- _tDrug abuse -- _g37. _tDrug abuse 1 : basic considerations -- _tDefinitions -- _tDiagnostic criteria for substance abuse and substance dependence -- _tFactors that contribute to drug abuse -- _tneurobiology of addiction -- _tPrinciples of addiction treatment -- _tThe Controlled Substance Act -- _g38. _tDrug abuse 2 : alcohol -- _tBasic pharmacology of alcohol -- _tAlcohol abuse -- _tDrugs employed in alcohol abuse treatment -- _g39. _tDrug abuse 3 : major drugs of abuse (other than alcohol) -- _tHeroin and other opioids -- _tGeneral CNS depressants -- _tPsychostimulants -- _tMarijuana and related preparations -- _tPsychedelics -- _t3, 4-methylenedioxymethamphetamine (MDMA, Ecstasy) -- _tPhencyclidine -- _tInhalants -- _tNicotine and smoking -- _tAnabolic steroids |
| 505 | 0 | 0 |
_g[pt]. 6. _tDrugs that affect fluid and electrolyte balance -- _g40. _tDiuretics -- _tReview of renal anatomy and physiology -- _tIntroduction to diuretics -- _tHigh-ceiling (loop) diuretics -- _tThiazides and related diuretics -- _tThiazides and related diuretics -- _tPotassium-sparing diuretics -- _tOsmotic diuretics -- _g41. _tAgents affecting the volume and ion content of body fluids -- _tDisorders of fluid volume and osmolality -- _tAcid-base disturbances -- _tPotassium imbalances -- _tMagnesium imbalances -- _g[pt]. 7. _tDrugs that affect the heart, blood vessels, and blood -- _g42. _tReview of hemodynamics -- _tOverview of the circulatory system -- _tRegulation of cardiac output -- _tRegulation of arterial pressure -- _g43. _tDrugs acting on the renin-angiotensin-aldosterone system -- _tPhysiology of the renin-angiotensin-aldosterone system -- _tAngiotensin-converting enzyme inhibitors -- _tAngiotensin 2 receptor blockers -- _tAldosterone antagonists -- _g44. _tCalcium channel blockers -- _tCalcium channels : physiologic functions and consequences of blockade -- _tCalcium channel blockers : classification and sites of action -- _tVerapamil and diltiazem : agents that act on vascular smooth muscle and the heart -- _tDihydropyridines : agents that act mainly on vascular smooth muscle |
| 505 | 0 | 0 |
_g45. _tVasodilators -- _tBasic concepts invasodilator pharmacology -- _tPharmacology of individual vasodilators -- _g46. _tDrugs for hypertension -- _tClassification of blood pressure -- _tTypes of hypertension -- _tConsequences of hypertension -- _tManagement of chronic hypertension 1 : basic considerations -- _tManagement of chronic hypertension 2 : lifestyle modifications -- _tManagement of chronic hypertension 3 : drug therapy -- _tDrugs for hypertensive emergencies -- _tDrugs for hypertensive disorders of pregnancy -- _g47. _tDrugs for heart failure -- _tPathophysiology of heart failure -- _tOverview of drugs used to treat heart failure -- _tCardiac (digitalis) glycosides -- _tManagement of heart failure -- _g48. _tAntidysrhythmic drugs -- _tElectrical properties of the heart -- _tGeneration of dysrhythmias -- _tClassification of antidysrhythmic drugs -- _tProdysrhythmic effects of antidysrhythmic drugs -- _tOverview of common dysrhythmias and their treatment -- _tClass 1 : sodium channel blockers -- _tClass 2 : beta blockers -- _tClass 3 : potassium channel blockers (drugs that delay repolarization) -- _tClass 4 : calcium channel blockers -- _tOther antidysrhythmic drugs -- _tPrinciples of antidysrhythmic drug therapy -- _tNondrug treatment of dysrhythmias |
| 505 | 0 | 0 |
_g49. _tProphylaxis of coronary heart disease : drugs that lower LDL cholesterol levels -- _tCholesterol -- _tPlasma lipoproteins -- _tRole of LDL cholesterol in atherosclerosis -- _tDetection, evaluation, and treatment of high cholesterol : recommendations from ATP 3 -- _tDrugs and other products used to alter plasma lipid levels -- _g50. _tDrugs for angina pectoris -- _tDeterminants of cardiac oxygen demand and oxygen supply -- _tAngina pectoris : pathophysiology and treatment strategy -- _tOrganic nitrates -- _tBeta blockers -- _tCalcium channel blockers -- _tRevascularization therapy : CABG and PCI -- _tSummary of treatment measures -- _g51. _tAnticoagulant, antiplatelet, and thrombolytic drugs -- _tPhysiology and pathophysiology of coagulation -- _tOverview of drugs used to treat thromboembolic disorders -- _tParenteral anticoagulants 1 : heparin and related drugs -- _tParenteral anticoagulants 2 : direct thrombin inhibitors -- _tWarfarin, and oral anticoagulant -- _tAntiplatelet drugs -- _tThrombolytic drugs -- _g52. _tManagement of ST-elevation myocardial infarction -- _tPathophysiology of STEMI -- _tDiagnosis of STEMI -- _tManagement of STEMI -- _tComplications of STEMI -- _tSecondary prevention of STEMI -- _g53. _tDrugs for hemophilia -- _tBasic considerations -- _tPreparations used to treat hemophilia -- _g53. _tDrugs for deficiency anemias -- _tRed blood cell development -- _tIron deficiency -- _tVitamin B₁₂ deficiency -- _tFolic acid defficiency -- _g55. _tHematopoietic growth factors -- _tErythropoietic growth factors -- _tLuekopoietic growth factors -- _tThrombopoietic growth factor |
| 505 | 0 | 0 |
_g[pt]. 8. _tDrugs for endocrine disorders -- _g56. _tDrugs for diabetes mellitus -- _tDiabetes mellitus : overview of the disease and its treatment -- _tInsulin 1 : physiology-- _tInsulin 2 : preparations and administration -- _tInsulin 3 : therapeutic use -- _tOral hypoglycemics for type 2 diabetes -- _tNew injectable drugs for diabetes -- _tDiabetic ketoacidosis -- _tGlucagon for insulin overdose -- _g57. _tDrugs for thyroid disorders -- _tThyroid physiology -- _tThyroid function tests -- _tThyroid pathophysiology -- _tThyroid hormone preparations for hypothyroidism -- _tDrugs for hyperthyroidism -- _g58. _tDrugs related to hypothalamic and pituitary function -- _tOverview of hypothalamic and pituitary endocrinology -- _tGrowth hormone -- _tProlactin -- _tThyrotropin -- _tCorticotropin -- _tGonadotropins -- _tAntidiuretic hormone -- _tOxytoxin -- _tDrugs related to hypothalamic function -- _g59. _tDrugs for disorders of the adrenal cortex -- _tPhysiology of the adrenocortical hormones -- _tPathophysiology of the adrenocortical hormones -- _tAgents for replacement therapy in adrenocortical insufficiency -- _tAgents for diagnostic testing of adrenocortical function -- _tInhibitors of corticosteroid synthesis |
| 505 | 0 | 0 |
_g[pt]. 9. _tWomen's health -- _g60. _tEstrogens and progestins : basic pharmacology and noncontraceptive applications -- _tThe menstrual cycle -- _tEstrogens -- _tSelective estrogen receptor modulators (SERMs) -- _tProgestins -- _tMenopausal hormone therapy -- _g61. _tBirth control -- _tEffectiveness and safety of birth control methods -- _tSelecting a birth control method -- _tOral contraceptives -- _tCombination contraceptives with novel delivery systems -- _tLong-acting contraceptives -- _tSpermicides -- _tBarrier devices -- _tDrugs for medical abortion -- _g62. _tDrug therapy of infertility -- _tInfertility : causes and treatment strategies -- _tDrugs used to treat female infertility -- _g63. _tDrugs that affect uterine function -- _tUterine relaxants (tocolytics) and their use in preterm labor -- _tUterine stimulants (oxytocicis) -- _tDrugs used to promote cervical ripening -- _g[pt]. 10. _tMen's health -- _g64. _tAndrogens -- _tTestosterone -- _tClinical pharmacology of the androgens -- _tAndrogen (anabolic steroid) abuse by athletes -- _g65. _tDrugs for erectile dysfunction and benign prostatic hyperplasia -- _tErectile dysfunction -- _tBenign prostatic hyperplasia |
| 505 | 0 | 0 |
_g[pt.] 11. _tAnti-inflammartory, antiallergic, and immunologic drugs -- _g66. _tReview of the immune system -- _tIntroduction to the immune system -- _tAntibody-mediated (humoral) immunity -- _tCell-mediated immunity -- _g67. _tChildhood immunization -- _tGeneral considerations -- _tTarget diseases -- _tSpecific vaccines and toxoids -- _g68. _tImmunosuppressants -- _tCalcineurin inhibitors -- _tSirlimus -- _tGlucocorticoids -- _tCytotoxic drugs -- _tAntibodies -- _g69. _tAntihistamines -- _tHistamine -- _tThe two types of antihistamines : H₁ antagonists and H₂ antagonists -- _tH₁ antagonists 1 : basic pharmacology -- _tH₁ antagonists 2 : preparations -- _g70. _tCyclooxygenase inhibitors : nonsteroidal anti-inflammatory drugs and acetaminophen -- _tMechanism of action -- _tClassificationod cyclooxygenase inhibitors -- _tFirst-generation NSAIDs -- _tSecond-generation NSAIDs (COX-2 inhibitors, coxibs) -- _tAcetaminophen -- _g71. _tGlucocorticoids in nonendocrine diseases -- _tReview of glucocorticoid physiology -- _tPharmacology of the glucocorticoids -- _g[pt]. 12. _tDrugs for bone and joint disorders -- _g72. _tDrug therapy of rheumatoid arthritis and gout -- _tDrug therapy of rheumatoid arthritis -- _tDrug therapy of gout -- _g73. _tDrugs affecting calcium levels and bone mineralization -- _tCalcium physiology -- _tCalcium-related pathophysiology-- _tDrugs for disorders involving calcium -- _tOsteoporosis |
| 505 | 0 | 0 |
_g[pt]. 13. _tRespiratory tract drugs -- _g74. _tDrugs for asthma -- _tPathophysiology of asthma -- _tOverview of drugs for asthma -- _tAdministration of drugs by inhalation -- _tBeta₂-adrenergic agonists -- _tGlucocorticoids -- _tGlucocorticoid/Beta₂ agonist combination -- _tCromolyn -- _tNedocromil -- _tMethylxanthines -- _tAnticholinergic drugs -- _tLeukotriene modifiers -- _tOmalizumab -- _tManagement of asthma -- _g75. _tDrugs for allergic rhinitis, cough, and colds -- _tDrugs for allergic rhinitis -- _tDrugs for cough -- _tCold remedies : combination preparations -- _g[pt]. 14. _tGastrointestinal drugs -- _g76. _tDrugs for peptic ulcer disease -- _g77. _tLaxatives -- _g78. _tOther gastrointestinal drugs -- _tAntiemetics -- _tDrugs for motion sickness -- _tAntidiarrheal agents -- _tDrugs for irritable bowel syndrome -- _tDrugs for inflammatory bowel disease -- _tProkinetic agents -- _tPalifermin -- _tPancreatic enzymes -- _tDrugs used to dissolve gallstones -- _tAnorectal preparations -- _g15. _tNutrition -- _g79. _tVitamins -- _tGeneral considerations -- _tFat-soluble vitamins -- _tWater-soluble vitamins -- _g80. _tEnteral and parenteral nutrition -- _tEnteral nutritional therapy -- _tParenteral nutritional therapy -- _tDrugs for obesity -- _tAssessment of obesity-related health risk -- _tOverview of obesity treatment -- _tWeight-loss drugs approved for long-term use -- _tMiscellaneous appetite suppressants -- _tInvestigational weight-loss drugs -- _tCalorie-saving foods |
| 505 | 0 | 0 |
_g[pt]. 16. _tChemotherapy of infectious diseases -- _g82. _tBasic principles of antimicrobial therapy -- _tSelective toxicity -- _tClassification of antimicrobial drugs -- _tAcquired resistance to antimicrobial drugs -- _tSelection of antibiotics -- _tHost factors that modify drug choice, route of administration, or dosage -- _tDosage size and duration of treatment -- _tTherapy with antibiotic combinations -- _tProphylactic use of antimicrobial drugs -- _tMisuses of antimicrobial drugs -- _tMonitoring antimicrobial therapy -- _g83. _tDrugs that weaken the bacterial cell wall 1 : penicillins -- _tIntroduction to the penicillins -- _tProperties of individual penicillins -- _g84. _tDrugs that weaken the bacterial cell wall 2 : cephalosporins, carbapenems, vancomycin, aztreonam, teicoplanin, and fosfomycin -- _tCephalosporins -- _tCarbapenems -- _tOther inhibitors of cell wall synthesis -- _g85. _tBacteriostatic inhibitors of protein synthesis : tetracyclines, macrolides and others -- _tTetracyclines -- _tMacrolides -- _tOther bacteriostatic inhibitors of protein synthesis -- _g86. _tAminoglycosides : bactericidal inhibitors of protein synthesis -- _tBasic pharmacology of the aminoglycosides -- _g87. _tSulfonamides and trimethoprim -- _tSulfonamides -- _tTrimethoprim -- _tTrimethoprim/sulfamethoxazole -- _g88. _tDrug therapy of urinary tract infections -- _tOrganisms that cause urinary tract infections -- _tSpecific urinary tract infections and their treatment -- _tUrinary tract antiseptics |
| 505 | 0 | 0 |
_g89. _tAntimycobacterial agents : drugs for tuberculosis, leprosy, and mycobacterium avium complex infection -- _tTuberculosis 1 : clinical considerations -- _tTuberculosis 2 : pharmacology of individual antituberculosis drugs -- _tDrugs for leprosy (Hansen's disease) -- _tDrugs for mycobacterium avium complex infection -- _g90. _tMiscellaneous antibacterial drugs : fluoroquinolones, metronidazole, daptomycin, rifampin, bacitracin, and polymyxins -- _tFluoroquinolones -- _tAdditional antibacterial drugs -- _g91. _tAntifungal agents -- _tDrugs for systemic mycoses -- _tDrugs for superficial mycoses -- _g92. _tAntiviral agents 1 : drugs for non-HIV viral infections -- _tDrugs for infection with herpes simplex viruses and varicella-zoster virus -- _tDrugs for cytomegalovirus infection -- _tDrugs for hepatitis -- _tDrugs for influenza -- _tDrugs for respiratory syncytial virus infection -- _g93. _tAntiviral agents 2 : drugs for HIV infection and related opportunistic infections -- _tPathophysiology -- _tClassification of antiretroviral drugs -- _tNucleoside/nucleotide reverse transcriptase inhibitors -- _tNon-nucleoside reverse transcriptase inhibitors -- _tProtease inhibitors -- _tEnfuvirtide, an HIV fusion inhibitor -- _tManagement of HIV infection -- _tProphylaxis and treatment of opportunistic infections -- _tHIV vaccines -- _tKeeping current |
| 505 | 0 | 0 |
_g94. _tDrug therapy of sexually transmitted diseases -- _tChlamydia trachomatis infections -- _tGonococcal infections -- _tNongonococcal urethritis -- _tPelvic inflammatory disease -- _tAcute epididymitis -- _tSyphilis -- _tAcquired immunodeficiency syndrome -- _tChancroid -- _tTrichomoniasis -- _tBacterial vaginosis -- _tHerpes simplex virus infections -- _tGenital and anal warts (condylomata acuminata) -- _tProctitis -- _g95. _tAntiseptics and disinfectants -- _tGeneral considerations -- _tProperties of individual antiseptics and disinfectants -- _tHand hygiene for healthcare workers -- _g[pt]. 17. _tChemotherapy of parasitic diseases -- _g96. _tAnthelmintics -- _tClassification of parasitic worms -- _tHelminthic infestations -- _tDrugs of choice for helminthiasis -- _g97. _tAntiprotozoal drugs 1: antimalarial agents -- _tLife cycle of the malaria parasite -- _tTypes of malaria -- _tPrinciples of antimalarial therapy -- _tPharmacology of the major antimalarial drugs -- _g98. _tAntiprotozoal drugs 2 : miscellaneous agents -- _tProtozoal infections -- _tDrugs of choice for protozoal infections -- _g99. _tEctoparasiticides -- _tEctoparasitic infestations -- _tPharmacology of ectoparasiticides |
| 505 | 0 | 0 |
_g[pt]. 18. _tCancer chemotherapy -- _g100. _tBasic principles of cancer chemotherapy -- _tWhat is cancer? -- _tThe growth fraction and its relationship to chemotherapy -- _tObstacles to successful chemotherapy -- _tStrategies for achieving maximum benefits from chemotherapy -- _tMajor toxicities of chemotherapeutic drugs -- _tMaking the decision to treat -- _tLooking ahead -- _g101. _tAnticancer drugs 1: cytotoxic agents -- _tIntroduction to the cytotoxic anticancer drugs -- _tAlkylating agents -- _tPlatinum compounds -- _tAntimetabolites -- _tAntitumor antibiotics -- _tMitotic inhibitors -- _tMitotic inhibitors -- _tTopoisomerase inhibitors -- _tMiscellaneous cytotoxic drugs -- _g102. _tAnticancer drugs 2 : hormonal agents, biologic response modifiers, and targeted drugs -- _tGlucocorticoids -- _tDrugs for prostate cancer -- _tDrugs for breast cancer -- _tBiologic response modifiers : immunostimulants -- _tTargeted drugs -- _g[pt]. 19. _tAdditional important drugs -- _g103. _tDrugs for the eye -- _tDrugs for glaucoma -- _tCycloplegics and mydriatics -- _tDrugs for allergic conjunctivitis -- _tDrugs for age-related macular degeneration -- _tAdditional ophthalmic drugs |
| 505 | 0 | 0 |
_g104. _tDrugs for the skin -- _tAnatomy of the skin -- _tTopical glucocorticoids -- _tKeratolytic agents -- _tAcne -- _tSunscreens -- _tPsoriasis -- _tOther dermatologic drugs -- _g105. _tDrugs for the ear -- _tAnatomy of the ear -- _tOtitis media and its management -- _tOtitis externa and its management -- _g106. _tMiscellaneous noteworthy drugs -- _tDrugs for pulmonary arterial hypertension -- _tDrotrecogin Alfa (activated) for severe sepsis -- _tDrugs for neonatal respiratory distress syndrome -- _tDrugs for cystic fibrosis -- _tDrugs for sickle cell anemia -- _tDrugs for hyperuicemia caused by cancer chemotherapy -- _tGamma-hydroxybutyrate for cataplexy in patients with narcolepsy -- _tRiluzole for amyotrophic lateral sclerosis -- _g[pt]. 20. _tAlternative therapy -- _g107. _tHerbal supplements -- _tLimited regulation : the Dietary Supplement Health and Education Act -- _tAdverse interactions with conventional drugs -- _tOral formulations -- _tStandardization of herbal products -- _tDosage -- _tSome commonly used medicinal herbs |
| 505 | 0 | 0 |
_g[pt]. 21. _tToxicology -- _g108. _tManagement of poisoning -- _tFundamentals of treatment -- _tDrugs and procedures used to minimize poison absorption -- _tDrugs and procedures used for poison removal -- _tSpecific antidotes -- _tPoison control centers -- _g109. _tPotential weapons of biologic, radiologic, and chemical terrorism -- _tBacteria and viruses -- _tBiotoxins -- _tChemical weapons -- _tRadiologic weapons -- _tAppendixes -- _gA. _tAdult immunization -- _gB. _tGuide to gender-related drugs -- _gC. _tPronunciation of generic drug names -- _gD. _tWeights and measures -- _gE. _tNormal laboratory values -- _gF. _tCommonly used abbreviations -- _gG. _tTechniques of drug administration -- _gH. _tPoison Control Centers in the United States -- _gI. _tCanadian drug information -- _gJ. _tMajor drug classes and their prototypes -- _gK. _tVery new drugs and important new formulations of older drugs |
| 538 | _aSystem requirements for Windows: Windows 98se, 2000, or XP ; Pentium II 400 MHz or faster processor ; at least 64 MB RAM recommended ; 10 MB free hard disk space ; 48X or faster CD-ROM drive ; 800 x 600 monitor with True Color | ||
| 538 | _aSystem requirements for Macintosh: OS X or greater ; Power Macintosh ; at least 64 MB RAM recommended ; 1 GHz+ PowerPC G4 ; 10 MB free hard disk space ; 48X or faster CD-ROM drive ; 800 x 600 monitor with Millions of colors | ||
| 650 | 0 |
_aPharmacology _93844 |
|
| 650 | 0 |
_aNursing _93976 |
|
| 650 | 1 | 2 |
_aPharmacology _93844 |
| 650 | 1 | 2 |
_aDrug Therapy _93869 |
| 655 | 2 |
_aNurses' Instruction _93887 |
|
| 942 |
_2lcc _cBK |
||
| 999 |
_c3488 _d3488 |
||